Galvanize Therapeutics Raises $130 Million in Oversubscribed Series D Financing to Accelerate Commercial Growth and Advance PEF Innovation
Article excerpt
Highlighted: the sentence this signal was extracted from
HealthQuest Capital leads financing to support Aliya commercial expansion, clinical evidence generation, pipeline advancement, and development of next-generation pulsed electric field ablation platforms REDWOOD CITY, Calif., Nov. 16, 2026 /PRNewswire/ -- Galvanize Therapeutics ® , a commercial-stage company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease, today announced the closing of an oversubscribed $130 million Series D financing. The round was
